Last month brought changes to thirty-five (35) medical product labels (down from 43 changes in April), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.
For a complete detailed accounting of the label changes, please refer to the summary of meds. By clicking onto the drug name, you can view the detailed summary, which will identify the safety labeling section and revised subsection, and a brief summary of the new or modified safety information.
The following medications have been affected:
Bepreve (bepotastine besilate) 1.5% ophthalmic
CellCept (mycophenolate mofetil)
CellCept (mycophenolate mofetil hydrochloride)
Estraderm (estradiol) transdermal
Helidac Therapy (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride)
Jalyn (dutasteride and tamsulosin HCL)
Methergine (methylergonovine maleate)
Myfortic (mycophenolic acid)
Prinivil (lisinopril) tablets and
Privigen Immune Globulin Intravenous (Human) 10%
Strattera (atomoxetine hydrochloride)
Vesicare (solifenacin succinate)